Radiobromine-labelled tracers for positron emission tomography: Possibilities and pitfalls

Current Radiopharmaceuticals

Volumn 4, Issue 2, 2011, Pages 76-89

  Tolmachev, Vladimir ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

76Br BFU; 76Br MBBG; Antibody; Bromine 75; Bromine 76; Labelling; Positron emission tomography; Targeting

Indexed keywords

(3 IODOBENZYL)GUANIDINE BR 76; (4 ISOTHIOCYANATOBENZYL AMMONIO) UNDECAHYDRO CLOSO DODECABORATE; 3' FLUOROTHYMIDINE F 18; 5 BROMO 2' DEOXYURIDINE BR 76; 5 BROMO 2' FLUORO 2' DEOXYURIDINE BR 76; BENZOIC ACID DERIVATIVE; BROMINE 75; BROMINE 76; CARBOXYLIC ACID DERIVATIVE; CLEVUDINE; HALOGEN; ISOTHIOCYANATOBENZYL 7,8 DICARBA NIDO UNDECABORATE; N SUCCINIMIDYL 4 TRIMETHYLSTANNYL BENZOATE; N SUCCINIMIDYL 5 (TRIBUTYLSTANNYL) 3 PYRIDINECARBOXYLATE BR 76; NORADRENALIN TRANSPORTER; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; TORASEMIDE; TRASTUZUMAB; UNCLASSIFIED DRUG;

ARTICLE; BROMINATION; DNA SYNTHESIS; DRUG EXCRETION; DRUG HALF LIFE; DRUG UPTAKE; ELECTROPHILICITY; ISOTOPE LABELING; ISOTOPE TRACING; NEUROBLASTOMA; NONHUMAN; PARAGANGLIOMA; PHEOCHROMOCYTOMA; POSITRON; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN TARGETING; RADIOACTIVITY; RADIOIODINATION; RADIOISOTOPE DIAGNOSIS; RADIOISOTOPE DISTRIBUTION; STRUCTURE ACTIVITY RELATION; TUMOR SCINTISCANNING;

ANIMALS; BROMINE RADIOISOTOPES; HUMANS; MICE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 79958717562     PISSN: 18744710     EISSN: 18744729     Source Type: Journal    
DOI: 10.2174/1874471011104020076     Document Type: Article

References (82)

1. Tolmachev, V.; Stone-Elander, S. Radiolabelled proteins for positron emission tomography: Pros and cons of labelling methods. Biochim. Biophys. Acta, 2010, 1800(5), 487-510.
2. Nayak, T.K.; Brechbiel, M.W. Radioimmunoimaging with longerlived positron-emitting radionuclides: potentials and challenges. Bioconjug. Chem., 2009, 20(5), 825-841.
3. Lubberink, M.; Schneider, H.; Bergström, M.; Lundqvist, H. Quantitative imaging and correction for cascade gamma radiation of 76Br with 2D and 3D PET. Phys. Med. Biol., 2002, 47(19), 3519-3534.
4. Laforest, R.; Liu, X. Image quality with non-standard nuclides in PET. Q. J. Nucl. Med. Mol. Imaging, 2008, 52(2), 151-158.
5. Qaim, S.M. Decay data and production yields of some nonstandard positron emitters used in PET. Q. J. Nucl. Med. Mol. Imaging, 2008, 52(2), 111-120.
6. Lundqvist H, Tolmachev V. Targeting peptides and positron emission tomography. Biopolymers, 2002, 66(6), 381-392.
7. Tolmachev, V.; Lövqvist, A.; Einarsson, L.; Schultz, J., Lundqvist, H. Production of 76Br by a low-energy cyclotron. Appl. Radiat. Isot., 1998, 49(12), 1537-1540.
8. Kloster, G.; Laufer, P.; Wutz, W.; Stöcklin, G. 75,77 Br- and 123 Ianalogues of D-glucose as potential tracers for glucose utilization in heart and brain. Eur. J. Nucl. Med., 1983, 8(6), 237-241.
9. Moerlein, S.M.; Stöcklin, G.L. Synthesis of high specific activity [75Br]- and [77Br]bromperidol and tissue distribution studies in the rat. J. Med. Chem., 1985, 28(9), 1319-1324.
10. Moerlein, S.M.; Laufer, P.; Stöcklin, G.; Pawlik, G.; Wienhard, K.; Heiss, W.D. Evaluation of 75Br-labelled butyrophenone neuroleptics for imaging cerebral dopaminergic receptor areas using positron emission tomography. Eur. J. Nucl. Med., 1986, 12(4), 211-126.
11. DeJesus, O.T.; Van Moffaert, G.J.; Friedman, A.M. Evaluation of positron-emitting SCH 23390 analogs as tracers for CNS dopamine D1 receptors. Int. J. Rad. Appl. Instrum. B, 1989, 16(1) 47-50.
12. van Dongen, G.A.; Visser, G.W.; Lub-de Hooge, M.N.; de Vries, E.G.; Perk, L.R. Immuno-PET: a navigator in monoclonal antibody development and applications. Oncologist, 2007, 12(12), 1379-1389.
13. Tolmachev, V.; Stone-Elander, S.; Orlova, A. Radiolabelled receptor-tyrosine-kinase targeting drugs for patient stratification and monitoring of therapy response: prospects and pitfalls. Lancet Oncol., 2010, 11(10), 992-1000.
14. van Dongen, G.A.; Vosjan, M.J. Immuno-positron emission tomography: shedding light on clinical antibody therapy. Cancer Biother. Radiopharm., 2010, 25(4), 375-385.
15. Grönwall, C.; Ståhl, S. Engineered affinity proteins--generation and applications. J. Biotechnol., 2009, 140(3-4), 254-269
16. Miao, Z.; Levi, J.; Cheng, Z. Protein scaffold-based molecular probes for cancer molecular imaging. Amino Acids, 2010, DOI: 10.1007/s00726-010-0503-9
17. Hong, H.; Zhang, Y.; Sun, J.; Cai, W. Positron emission tomography imaging of prostate cancer. Amino Acids, 2010, 39(1), 11-27.
18. Chen, K.; Conti, P.S. Target-specific delivery of peptide-based probes for PET imaging. Adv. Drug. Deliv. Rev., 2010, 62(11), 1005-1022.
19. Mattes, M.J.; Griffiths, G.L.; Diril, H.; Goldenberg, D.M.; Ong, G.L., Shih, L.B. Processing of antibody-radioisotope conjugates afterbinding to the surface of tumor cells. Cancer, 1994, 73(3 Suppl), 787-793.
20. Shih, L.B.; Thorpe, S.R.; Griffiths, G.L.; Diril, H.; Ong, G.L.; Hansen, H.J.; Goldenberg, D.M.; Mattes, M.J. The processing and fate of antibodies and their radiolabels bound to the surface of tumor cells in vitro: a comparison of nine radiolabels. J. Nucl. Med., 1994, 35(5), 899-908.
21. Press, O.W.; Shan, D.; Howell-Clark, J.; Eary, J.; Appelbaum, F.R.; Matthews, D.; King, D.J.; Haines, A.M.; Hamann, P.; Hinman, L.; Shochat, D.; Bernstein, I.D. Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. Cancer Res., 1996, 56(9), 2123-2129.
22. Behr, T.M.; Gotthardt, M.; Barth, A.; Béhé, M. Imaging tumors with peptide-based radioligands. Q. J. Nucl. Med., 2001, 45(2), 189-200.
23. Tolmachev, V.; Orlova, A.; Lundqvist, H. Approaches to improve cellular retention of radiohalogen labels delivered by internalizing tumour-targeting proteins and peptides. Curr. Med. Chem., 2003, 10(22), 2447-2260.
24. Behr, T.M.; Goldenberg, D.M.; Becker, W. Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations. Eur. J. Nucl. Med., 1998, 25(2), 201-212.
25. Wilbur, D.S. Radiohalogenation of proteins: an overview of radionuclides, labeling methods, and reagents for conjugate labeling. Bioconjug. Chem., 1992, 3(6), 433-470.
26. Lövqvist, A.; Sundin, A.; Ahlström, H.; Carlsson, J.; Lundqvist, H. 76Br-labeled monoclonal anti-CEA antibodies for radioimmuno positron emission tomography. Nucl. Med. Biol., 1995, 22(1), 125-131.
27. Sundin, J.; Tolmachev, V.; Koziorowski, J.; Carlsson, J.; Lundqvist, H.; Welt, S.; Larson, S.; Sundin, A. High yield direct 76Brbromination of monoclonal antibodies using chloramine-T. Nucl. Med. Biol., 1999, 26(8), 923-929.
28. Knight, L.C.; Welch, M.J. Sites of direct and indirect halogenation of albumin. Biochim. Biophys. Acta, 1978, 534(2), 185-195.
29. Nikula, T.K.; Bocchia, M.; Curcio, M.J.; Sgouros, G.; Ma, Y.; Finn, R.D.; Scheinberg, D.A. Impact of the high tyrosine fraction in complementarity determining regions: measured and predicted effects of radioiodination on IgG immunoreactivity. Mol. Immunol., 1995, 32(12), 865-872.
30. Olafsen, T.; Bruland, O.S.; Zalutsky, M.R.; Sandlie, I. Abundant tyrosine residues in the antigen binding site in anti-osteosarcoma monoclonal antibodies TP-1 and TP-3: Application to radiolabeling. Acta Oncol., 1996, 35(3), 297-301.
31. Smellie, W.J.; Dean, C.J.; Sacks, N.P.; Zalutsky, M.R.; Garg, P.K.; Carnochan, P.; Eccles, S.A. Radioimmunotherapy of breast cancer xenografts with monoclonal antibody ICR12 against c-erbB2 p185: comparison of iodogen and N-succinimidyl 4-methyl-3-(tri-nbutylstannyl) benzoate radioiodination methods. Cancer Res., 1995, 55(23 Suppl), 5842s-5846s.
32. Knight, L.C.; Krohn, R.A.; Welch, M. J.; Spomer, B.; Hager, L.P. In: Radiopharmaceuticals, Subramanian G. Ed.; Society of Nuclear Medicine: New York, 1975; pp. 149-154.
33. McElvany, K.D.; Welch, M.J. Characterization of bromine-77-labeled proteins prepared using bromoperoxidase. J. Nucl. Med., 1980, 21(10), 953-960.
34. Rossin, R.; Berndorff, D.; Friebe, M.; Dinkelborg, L.M.; Welch, M.J. Small-animal PET of tumor angiogenesis using a (76)Brlabeled human recombinant antibody fragment to the ED-B domain of fibronectin. J. Nucl. Med., 2007, 48(7), 1172-1179.
35. Zhao, Q.; Tolmachev, V.; Carlsson, J.; Lundqvist, H.; Sundin, J.; Janson, J.C.; Sundin, A. Effects of dextranation on the pharmacokinetics of short peptides. A PET study on mEGF. Bioconjug. Chem., 1999, 10(6), 938-446.
36. Höglund, J.; Orlova, A.; Sundin, A.; Lundqvist, H.; Tolmachev, V. Cellular processing in the SW1222 cell line of mAb A33 directly and indirectly radiohalogenated. Oncol. Rep., 2006, 16(1), 159-163.
37. Lövqvist, A.; Sundin, A.; Ahlström, H.; Carlsson, J.; Lundqvist, H. Pharmacokinetics and experimental PET imaging of a bromine-76-labeled monoclonal anti-CEA antibody. J. Nucl. Med., 1997, 38(3), 395-401.
38. Lee, H.; Finck, B.N.; Jones, L.A.; Welch, M.J.; Mach, R.H. Synthesis and evaluation of a bromine-76-labeled PPARgamma antagonist 2-bromo-5-nitro-N-phenylbenzamide. Nucl. Med. Biol., 2006, 33(7), 847-854.
39. Yngve, U.; Hedberg, E.; Lövqvist, A.; Tolmachev, V.; Långström, B. Synthesis of N-Succinimidyl 4-[76Br]Bromobenzoate and its Use in Conjugation Labelling of Macromolecules. Acta Chem. Scand., 1999, 53(7), 508-512.
40. Wu, F.; Lendvai, G.; Yngve, U., Eriksson, B.; Långström, B.; Bergström, M. Hybridisation of [76Br]-labelled antisense oligonucleotides to Chromogranin A mRNA verified by RT-PCR. Nucl. Med. Biol., 2004, 31(8), 1073-1078.
41. Höglund, J.; Tolmachev, V.; Orlova, A.; Lundqvist, H.; Sundin, A. Optimized indirect 76Br-bromination of antibodies using Nsuccinimidyl para-[76Br]bromobenzoate for radioimmuno PET. Nucl. Med. Biol., 2000, 27(8), 837-843.
42. Orlova, A.; Höglund, J.; Lubberink, M.; Lebeda, O.; Gedda, L.; Lundqvist, H.; Tolmachev, V.; Sundin, A. Comparative biodistribution of the radiohalogenated (Br, I and At) antibody A33. Implications for in vivo dosimetry. Cancer. Biother. Radiopharm., 2002, 17(4), 385-396.
43. Garg, S.; Garg, P.K.; Zalutsky, M.R. N-succinimidyl 5- (trialkylstannyl)-3-pyridinecarboxylates: a new class of reagents forprotein radioiodination. Bioconjug. Chem., 1991, 2(1), 50-56.
44. Garg, S.; Garg, P.K.; Zhao, X.G.; Friedman, H.S.; Bigner, D.D.; Zalutsky, M.R. Radioiodination of a monoclonal antibody using N -succinimidyl 5-iodo-3-pyridinecarboxylate. Nucl. Med. Biol., 1993, 20(7), 835-842.
45. Reist, C.J.; Archer, G.E.; Wikstrand, C.J.; Bigner, D.D., Zalutsky, M.R. Improved targeting of an anti-epidermal growth factor receptor variant III monoclonal antibody in tumor xenografts after labeling using N-succinimidyl 5-iodo-3-pyridinecarboxylate. Cancer Res., 1997, 57(8), 1510-1515.
46. Reist, C.J.; Foulon, C.F.; Alston, K.; Bigner, D.D.; Zalutsky, M.R. Astatine-211 labeling of internalizing anti-EGFRvIII monoclonal antibody using N-succinimidyl 5-[211At]astato-3-pyridinecarboxylate. Nucl. Med. Biol., 1999, 26(4), 405-411.
47. Mume, E.; Orlova, A.; Malmström, P.U.; Sjöberg, S.; Tolmachev, V. Radiobromination of humanized anti-HER2 monoclonal antibody trastuzumab using N-succinimidyl 5 bromo-3- pyridinecarbocylate, a potential label for immunoPET. Nucl. Med. Biol., 2005, 32(6), 613-622.
48. Tolmachev, V.; Sjöberg, S. Polyhedral boron compounds as potential linkers for attachment of radiohalogens to targeting proteins and peptides. Coll. Czech. Chem. Comm., 2003, 67(7), 913-935.
49. Tolmachev, V.; Bruskin, A.; Sivaev, I.; Lundqvist, H.; Sjöberg, S. Radiobromination of closo-dodecaborate anion. Aspects of labeling chemistry in aqueous solutions using Chloramine-T. Radiochim. Acta, 2002, 90(4), 229-235.
50. Wilbur, D.S.; Chyan, M.K.; Hamlin, D.K.; Vessella, R.L; Wedge, T.J., Hawthorne, M.F. Reagents for astatination of biomolecules. 2.Conjugation of anionic boron cage pendant groups to a protein providesa method for direct labeling that is stable to in vivo deastatination. Bioconjug. Chem., 2007, 18(4), 1226-1240.
51. Sivaev, I.B.; Bruskin, A.B.; Nesterov, V.V.; Antipin, M.Y.; Bregadze, V.I.; Sjoberg, S. Synthesis of Schiff Bases Derived from the Ammoniaundecahydro-closo-dodecaborate(1-) Anion, [B12H11NH=CHR]-, and Their Reduction into Monosubstituted Amines [B12H11NH2CH2R]-: A New Route to Water Soluble Agents for BNCT. Inorg. Chem., 1999; 38(25), 5887-5889
52. Bruskin, A.; Sivaev, I.; Persson, M.; Lundqvist, H.; Sjöberg, S.; Tolmachev, V. Radiobromination of monoclonal antibody using isothiocyanato derivative of closo-dodecaborate ([76Br]Bromo-DABI). Nucl. Med. Biol., 2004, 31(2), 205-211.
53. Winberg, K.J.; Persson, M.; Malmström, P.U.; Sjöberg, S.; Tolmachev, V. Radiobromination of anti-HER2/neu/erbB-2monoclonal antibody using the p-isothiocyanatobenzene derivative of the [76Br]undecahydro-bromo-7,8-dicarba-nidoundecaborate(1-) ion. Nucl. Med. Biol., 2004, 31(4), 425-422.
54. Persson, M.; Sivaev, I.; Winberg, K.J.; Gedda, L.; Malmström, P.U.; Tolmachev, V. In vitro evaluation of two polyhedral boron anion derivatives as linkers for attachment of radioiodine to the anti-HER2 monoclonal antibody trastuzumab. Cancer Biother. Radiopharm., 2007, 22(5), 585-596.
55. Mume, E.; Orlova, A.; Nilsson, F.; Larsson, B., Nilsson, A.S.; Sjöberg, S.; Tolmachev, V. Evaluation of (4- hydroxyphenyl)ethyl)maleimide for site-specific radiobromination of anti-HER2 affibody. Bioconjug. Chem., 2005, 16(6), 1547-1555.
56. Olafsen, T.; Bruland, O.S.; Zalutsky, M.R.; Sandlie, I Cloning and sequencing of V genes from anti-osteosarcoma monoclonal antibodies TP-1 and TP-3: location of lysine residues and implications for radiolabeling. Nucl. Med. Biol., 1995, 22(6), 765-771.
57. Ahlgren, S.; Tolmachev, V. Radionuclide molecular imaging using Affibody molecules. Curr. Pharm. Biotechnol., 2010, 11(6), 581-589.
58. Langer, O.; Halldin, C. PET and SPET tracers for mapping the cardiac nervous system. Eur. J. Nucl. Med. Mol. Imaging, 2002, 29(3), 416-434.
59. Verberne, H.J.; Brewster, L.M.; Somsen, G.A.; Van Eck-Smit, B.L. Prognostic value of myocardial 123I-metaiodobenzylguanidine (MIBG) parameters in patients with heart failure: a systematic review. Eur. Heart J., 2008, 29(9), 1147-1159.
60. Jacobson, A.F.; Deng, H.; Lombard, J.; Lessig, H.J.; Black, R.R. 123I-meta-iodobenzylguanidine scintigraphy for the detection of neuroblastoma and pheochromocytoma: results of a meta-analysis. J. Clin. Endocrinol. Metab., 2010, 95(6), 2596-2606.
61. Bombardieri, E.; Coliva, A.; Maccauro, M.; Seregni, E.; Orunesu, E.; Chiti, A.; Lucignani, G. Imaging of neuroendocrine tumours with gamma-emitting radiopharmaceuticals. Q. J. Nucl. Med. Mol. Imaging, 2010, 54(1), 3-15.
62. Khan, M.U.; Morse, M.; Coleman, R.E. Radioiodinated metaiodobenzylguanidine in the diagnosis and therapy of carcinoid tumors. Q. J. Nucl. Med. Mol. Imaging, 2008, 52(4), 441-454.
63. Rufini, V; Calcagni, M.L.; Baum, R.P. Imaging of neuroendocrinetumors. Semin. Nucl. Med., 2006, 36(3), 228-247.
64. Watanabe, S.; Hanaoka, H.; Liang, J.X.; Iida, Y.; Endo, K.; Ishioka, N.S. PET imaging of norepinephrine transporter-expressing tumors using 76Br-meta-bromobenzylguanidine. J. Nucl. Med., 2010, 51(9), 1472-1479.
65. Bombardieri, E.; Giammarile, F.; Aktolun, C.; Baum, R.P.; Bischof Delaloye, A.; Maffioli, L.; Moncayo, R.; Mortelmans, L.; Pepe, G.; Reske, S.N.; Castellani, M.R., Chiti A. 131I/123Imetaiodobenzylguanidine (mIBG) scintigraphy: procedure guidelines for tumour imaging. Eur. J. Nucl. Med. Mol. Imaging, 2010, 37(12), 2436-2446.
66. Loc'h, C.; Mardon, K.; Valette, H.; Brutesco, C.; Merlet, P.; Syrota, A.; Maziere, B. Preparation and pharmacological characterization of [76Br]-meta-bromobenzylguanidine ([76Br]MBBG). Nucl. Med. Biol., 1994, 21(1), 49-55.
67. Valette, H.; Loc'h, C.; Mardon, K.; Bendriem, B.; Merlet, P.; Fuseau C. Sabry, S. Raffel, D. Mazière, B. Syrota, A. Bromine-76-metabromobenzylguanidine: a PET radiotracer for mapping sympathetic nerves of the heart. J. Nucl. Med., 1993, 34(10), 1739-1744.
68. Raffel, D.; Loc'h, C.; Mardon, K.; Mazière, B.; Syrota, A. Kinetics of the norepinephrine analog [76Br]-meta-bromobenzylguanidine in isolated working rat heart. Nucl. Med. Biol., 1998, 25(1), 1-16.
69. Clerc, J.; Mardon, K.; Galons, H.; Loc'h, C.; Lumbroso, J.; Merlet, P.; Zhu, J.; Jeusset, J.; Syrota, A.; Fragu, P. Assessing intratumor distribution and uptake with MBBG versus MIBG imaging and targeting xenografted PC12-pheochromocytoma cell line. J. Nucl. Med., 1995, 36(5), 859-866.
70. Weber, W.A. Monitoring tumor response to therapy with 18F-FLT PET. J. Nucl. Med., 2010, 51(6), 841-844.
71. Bading, J.R.; Shields, A.F. Imaging of cell proliferation: status and prospects. J. Nucl. Med., 2008, 49(Suppl 2), 64S-80S.
72. Mariani, G.; Cei, A.; Collecchi, P.; Baranowska-Kortylewicz, J; Van den Abbeele, A.D.; Di Luca, L.; Di Stefano, R.; Viacava, P.; Ferdeghini, E.M.; Di Sacco, S. Tumor targeting in vivo and metabolic fate of 5-[iodine-125]iodo-2'-deoxyuridine following intratumoral injection in patients with colorectal cancer. J. Nucl. Med., 1993, 34(7), 1175-1183.
73. Tjuvajev, J.; Muraki, A.; Ginos, J.; Berk, J.; Koutcher, J.; Ballon, D.; Beattie, B.; Finn, R.; Dahighian, F.; Blasberg, R. Iododeoxyuridine uptake and retention as a measure of tumor growth. J. Nucl. Med., 1993, 34(7), 1152-1162.
74. Tjuvajev, J.G.; Macapinlac, H.A.; Daghighian, F; Scott, A.M.; Ginos, J.Z.; Finn, R.D.; Kothari, P.; Desai, R.; Zhang, J.; Beattie, B.; Graham, M.; Larson, S.M.; Blasberg, R.G. Imaging of brain tumor proliferative activity with iodine-131-iododeoxyuridine. J. Nucl. Med., 1994, 35(9), 1407-1417.
75. Bergström, M.; Lu, L.; Fasth, K.J.; Wu, F.; Bergström-Pettermann, E., Tolmachev, V.; Hedberg, E.; Cheng, A.; Långström, B. In vitro and animal validation of bromine-76-bromodeoxyuridine as a proliferation marker. J. Nucl. Med., 1998, 39(7), 1273-1279.
76. Ryser, J.E.; Bläuenstein, P.; Rémy, N.; Weinreich, R.; Hasler, P.H.; Novak-Hofer, I.; Schubiger, P.A. [76Br]Bromodeoxyuridine, a potential tracer for the measurement of cell proliferation by positron emission tomography, in vitro and in vivo studies in mice. Nucl. Med. Biol., 1999, 26(6), 673-679.
77. Lu, L.; Bergström, M.; Fasth, K.J.; Wu, F.; Eriksson, B.; Långström, B. Elimination of nonspecific radioactivity from [76Br]bromide in PET study with [76Br]bromodeoxyuridine. Nucl. Med. Biol., 1999, 26(7), 795-802.
78. Böni, R., Bläuenstein, P.; Dummer, R.; von Schulthess, G.K.; Schubiger, P.A.; Steinert, H.C. Non-invasive assessment of tumour cell proliferation with positron emission tomography and [76Br]bromodeoxyuridine. Melanoma Res., 1999, 9(6), 569-573.
79. Gudjonsson, O.; Bergström, M.; Kristjansson, S.; Wu, F.; Nyberg., G, Fasth, K.J.; La °ngström, B. Analysis of 76Br-BrdU in DNA of brain tumors after a PET study does not support its use as a proliferation marker. Nucl. Med. Biol., 2001, 28(1), 59-65.
80. Blasberg, R.G.; Tjuvajev, J.G. Herpes simplex virus thymidine kinase as a marker/reporter gene for PET imaging of gene therapy. Q. J. Nucl. Med., 1999, 43(2):163-169.
81. Lu, L.; Bergström, M.; Fasth, K.J.; Langström, B. Synthesis of [76Br]bromofluorodeoxyuridine and its validation with regard to uptake, DNA incorporation, and excretion modulation in rats. J. Nucl. Med., 2000, 41(10), 1746-1752.
82. Lu, L.; Samuelsson, L.; Bergström, M.; Sato, K.; Fasth, K.J.; Långström, B. Rat studies comparing 11C-FMAU, 18F-FLT, and 76Br-BFU as proliferation markers. J. Nucl. Med., 2002, 43(12), 1688-1698.